BioAge Labs Execs to Present at Key Healthcare Conferences
Event summary
- BioAge Labs execs to present at Jefferies and Goldman Sachs healthcare conferences in June 2026
- CFO Dov Goldstein and CSO BJ Sullivan scheduled for fireside chats and one-on-one meetings
- Phase 2 cardiovascular risk data for BGE-102 expected by year-end 2026
- Phase 1b/2a diabetic macular edema data for BGE-102 anticipated mid-2027
The big picture
BioAge Labs' participation in high-profile investor conferences comes as the company advances its lead candidate BGE-102 through critical clinical stages. The presentations may provide new insights into the company's strategic direction amid growing interest in therapies targeting metabolic aging. With Phase 2 data approaching, BioAge's ability to communicate its value proposition effectively could influence its market positioning in the competitive biotech landscape.
What we're watching
- Clinical Milestones
- Whether BioAge can deliver on its Phase 2 cardiovascular risk data timeline by year-end 2026
- Investor Sentiment
- How conference presentations will impact investor perception of BioAge's pipeline and execution capabilities
- Competitive Positioning
- The pace at which BioAge can differentiate BGE-102 in the crowded NLRP3 inhibitor space
Related topics